Publications

Featured Publications

Pattern of Natural Killer (NK) Cell (CD16+CD56+) Expansion Correlates With Response Outcomes With Nemvaleukin Alfa Treatment

Society for Immunotherapy of Cancer (SITC) Annual Meeting

calendar icon November 2023


>> View Poster

ARTISTRY-7: Phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer

Future Oncology

calendar icon June 2023


>> View Article

Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors: ARTISTRY-1

American Society of Clinical Oncology (ASCO) Annual Meeting

calendar icon


>> View Presentation

All Publications

  • Filter by Indications

  • Filter by Clinical Study

  • Reset Filters

Use of Quantitative System Pharmacology (QSP) Modeling to Optimize Dosing Frequency and Interval for Nemvaleukin Alfa, an Investigational Cancer Immunotherapy

Population Approach Group Europe (PAGE) Meeting

calendar icon June 2022


>> View Poster

Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors: ARTISTRY-1

American Society of Clinical Oncology (ASCO) Annual Meeting

calendar icon


>> View Presentation

ARTISTRY-3: Effect of Nemvaleukin Alfa With a Less Frequent IV Dosing Schedule as Monotherapy and in Combination With Pembrolizumab and Impact on the Tumor Microenvironment in Patients With Advanced Solid Tumors

American Society of Clinical Oncology (ASCO) Annual Meeting

calendar icon June 2022


>> View Poster

ARTISTRY-6: Nemvaleukin Alfa Monotherapy in Patients With Advanced Mucosal and Cutaneous Melanoma

American Society of Clinical Oncology (ASCO) Annual Meeting

calendar icon June 2022


>> View Poster

Nemvaleukin Alfa Combination Therapy for Gastrointestinal (GI) Cancers: Preclinical Evidence and Clinical Data From the ARTISTRY-1 Trial

Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO GI)

calendar icon


>> View Poster

Use of Quantitative System Pharmacology (QSP) Modeling to Optimize Dosing Frequency and Interval for Nemvaleukin Alfa, an Investigational Cancer Immunotherapy

Quantitative Systems Pharmacology Conference

calendar icon April 2022


>> View Poster

ARTISTRY-7: a Phase 3, Multicenter Study of Nemvaleukin Alfa, a Novel Engineered Cytokine, in Combination With Pembrolizumab Versus Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Society of Gynecologic Oncology Annual Meeting on Women's Cancer

calendar icon March 2022


>> View Poster

Clinical outcomes of ovarian cancer patients treated with the novel engineered cytokine nemvaleukin alfa in combination with the PD-1 inhibitor pembrolizumab: recent data from ARTISTRY-1

Society of Gynecologic Oncology Annual Meeting on Women's Cancer

calendar icon March 2022


>> View Presentation

Nemvaleukin Alfa in Patients With Advanced Renal Cell Carcinoma: ARTISTRY-1

American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium

calendar icon February 2022


>> View Poster

Nemvaleukin Alfa Monotherapy in Patients With Advanced Melanoma: ARTISTRY-1

Melanoma Bridge

calendar icon December 2021


>> View Presentation

Nemvaleukin Alfa, a Novel Engineered IL-2 Cytokine, in Combination With the Anti-PD-1 Antibody Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (ION-01 Study)

Society for Immunotherapy of Cancer (SITC) Annual Meeting

calendar icon November 2021


>> View Poster

ARTISTRY-6: Nemvaleukin Alfa Monotherapy in Patients With Advanced Mucosal and Cutaneous Melanoma

Society for Melanoma Research Congress

calendar icon October 2021


>> View Poster